Global Dementia Drugs Market to Surpass US$ 39,663.6 Million by 2030, Says Coherent Market Insights (CMI)
July 26, 2022 08:40 ET
|
CMI
Seattle, July 26, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global dementia drugs market is estimated to be valued at US$ 20,677.0 million in 2022 and is expected to...
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
May 04, 2022 16:01 ET
|
Cyclerion Therapeutics, Inc.
Characterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking...
Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference
April 06, 2022 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., April 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
March 30, 2022 07:00 ET
|
Cognition Therapeutics, Inc.
- Well capitalized from $52 million IPO and $169 million in grant funding -- Established clinical program in Alzheimer’s disease enhanced by new DLB study and dry AMD program -- Conference call and...
ProMIS Neurosciences Announces Fiscal Year 2021 Results
March 17, 2022 07:00 ET
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused...
Cognition Therapeutics Announces Participation in March Investment Conferences
March 08, 2022 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., March 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX
February 25, 2022 20:45 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 25, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Cortexyme, Inc....
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
February 24, 2022 16:01 ET
|
Cyclerion Therapeutics, Inc.
Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment...
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease with Vascular Pathology
January 26, 2022 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...
Lui Franciosi To Assess the Safety and Efficacy of a New Dementia Treatment
January 05, 2022 16:00 ET
|
Franciosi Consulting Ltd.
VANCOUVER, British Columbia, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be reviewing and monitoring the safety and efficacy of the new...